Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Asthma is a common condition that can cause coughing, wheezing, chest tightness and breathlessness. About 1 in 10 people with asthma have difficult to control symptoms and are described as having severe asthma. They need more healthcare support than milder disease. We know regular physical activity has important health benefits, but many patients with severe asthma avoid exercise. GPs and nurses may also be worried that exercise might worsen asthma symptoms. Physical training through short structured supervised programmes (pulmonary rehabilitation [PR]) leads to improved symptoms, quality of life and fitness in other chronic lung diseases. They are good value for money and lead to less healthcare use. However, few patients with severe asthma have access to such programmes. Our local PR service has accepted these patients, but patients said they would prefer to attend a specific programme for asthma. The aim of this study is to find out whether people with severe asthma would benefit from a PR programme specifically for asthma.

Who can participate?
Patients with severe asthma.

What does the study involve?
Participants are randomly allocated to one of two groups. One group attends a PR programme specifically for asthma. The other group receives usual care (disease education and exercise advice from asthma nurses).

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Glenfield Hospital (UK)

When is the study starting and how long is it expected to run for?
December 2013 to November 2016

Who is funding the study?
National Institute for Health Research (NIHR) (UK)

Who is the main contact?
Dr Rachael Evans

Trial website

Contact information



Primary contact

Dr Rachael Evans


Contact details

Consultant Respiratory Physician
Glenfield Hospital
Groby Road
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number

CLRN 127552

Study information

Scientific title

A feasibility study to inform the development of a multicentre randomised controlled trial of an asthma-tailored pulmonary rehabilitation programme versus usual care for individuals with severe asthma


Study hypothesis

Patients with severe asthma have a high morbidity and healthcare cost despite currently available therapies. Activity limitation is common, leading to reduced health-related quality of life (HRQoL). Cardiorespiratory fitness (CRF) is a strong predictor of mortality and asthma has a strong inverse association with CRF. Despite this, patients with severe asthma are often excluded from exercise schemes due to perceived higher risks. Pulmonary rehabilitation (PR), with core components of exercise training and multi-professional education, is an integral part of the management of patients with chronic lung disease, with grade A evidence for improvements in dyspnoea, exercise tolerance and HRQoL. International guidance suggests inclusion of patients with asthma, but there is little published evidence evaluating either existing or tailored regimens in severe asthma, leading to few patients being referred. Our patients stated a preference for a PR programme specifically for their disease. We propose a feasibility study to inform the study design of a large multicentre randomised controlled trial (RCT) of asthma-tailored PR (AT-PR) for individuals with severe asthma compared to usual care (UC).

The aims of the proposed study are, in patients with severe asthma, to:
1. Understand the facilitators and barriers to regular physical activity and exercise
2. Understand healthcare professionals’ attitudes to exercise for this group
3. Perform a small scale version of the eventual RCT to:
3.1. Provide information on recruitment rate, retention rate, adverse events, accessibility and acceptability of the AT-PR programme, to assess the feasibility of the proposed study protocol, and to design and pilot a suitable patient cost questionnaire to be used in the proposed cost-effectiveness economic evaluation in the subsequent RCT
3.2. Identify further barriers or facilitators to participation in a AT-PR programme
4. To facilitate patient involvement in the design, conduct and dissemination for the multicentre trial.

Ethics approval

NRES Committee East Midlands - Leicester, 17/10/2013, ref: 13/EM/0323

Study design

Qualitative study and small scale feasibility study of a randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Severe asthma


This feasibility project uses the Medical Research Council (MRC) guidelines on developing a complex intervention. It will have four stages and adopts a mixed methods approach. Recruitment for each stage will be separate.

The project will be conducted as stages:
1. A qualitative study involving semi-structured interviews will explore attitudes to exercise
2. A qualitative study involving focus groups of healthcare professionals will explore attitudes to exercise for severe asthma
3. A small scale feasibility study of an RCT of AT-PR versus UC will be performed. A qualitative approach will be used to explore the facilitators and barriers to participation in a AT-PR and the study protocol. AT-PR, modelled on our local successful PR programme for chronic obstructive pulmonary disease (COPD), will be exclusively for severe asthma and further modified according to the findings from stage 1 and 2. Usual care (DAC) will include disease education and exercise advice from asthma nurses. We plan to randomise 40 patients to the intervention arm and 20 patients to usual care. We estimate conservatively that we will recruit 30% of those invited to estimate the recruitment rate with a precision of at least +/- 7%. We suggest a conservative dropout rate of 25% (our local PR dropout rate is approximately 15%); recruiting 40 patients to the AT-PR programme, the precision of the estimated retention rate would be at least +/- 14%. From experience to date, we are expecting very few serious adverse events relating to the exercise programme. Based on a rate of 2.5%, the rate would be estimated to be less than 13%. All precisions are based on two-sided 95% confidence intervals.
4. The patient involvement during the project will be assessed to make any necessary adaptations for the multicentre trial

Intervention type



Drug names

Primary outcome measure

To establish the practicality of a definitive multicentre RCT, the primary outcomes for the feasibility study are:
1. Recruitment rate
2. Retention rate
3. Incidence of adverse events

Secondary outcome measures

The outcome measures proposed for the multicentre trial will be included to assess patient acceptability of the tests, study protocol and data completion. The outcome measures to assess the intervention will be collected at baseline, 12 weeks and 6 months by a blinded investigator. We have experience in using all proposed outcome measures. Baseline demographics will be recorded including body mass index and spirometry.

1. Any adverse events directly or indirectly related to the exercise measurements and training sessions will be recorded. Any severe adverse event will be reported to our Research and Development office immediately. An external respiratory physician has agreed to independently assess any adverse events and stop the trial if necessary.
2. A full cardiopulmonary exercise test with expiratory gas analysis will be performed on a treadmill. Exercise-induced bronchoconstriction will be assessed by a flow-volume loop, before and after the treadmill test, before and after 12 weeks. All patients will be included in the programme and excluded only if they have an adverse event. This data will used as an outcome measure not just for safety.
3. Asthma control and disease activity will be assessed by:
3.1. The Juniper Asthma Control Score
3.2. Measuring airway inflammation by induced sputum count before and after the intervention
3.3. By comparing the preceeding 9 months unscheduled healthcare visits for asthma with 9 months after and including the intervention, including GP, accident and emergency attendance and hospital admissions.

Cost effectiveness
The Euroqol (EQ-5D) questionnaire will be used to assess quality-adjusted life-years (QALYs) at baseline, 12 weeks and 6 months. Costs will be calculated using NHS tariffs. All treatment including medication, adverse events and any over the counter medication will be recorded. Cost effectiveness will be assessed with the help of a health economist using methodology previously described.

The usual outcome measures for PR will be assessed to ensure acceptability of the protocol for the multicentre trial. As exercise rehabilitation is a complex medical intervention there are a number of different outcomes to assess including:
1. Asthma-specific health-related quality of life (HRQoL) using the asthma quality of life questionnaire (AQLQ) and Chronic Respiratory Questionnaire
2. Hospital Anxiety and Depression Scale
3. Incremental treatmill test (ITM)
4. Incremental shuttle walking test (ISWT)
5. Endurance shuttle walk test (ESWT)
6. Compliance with the supervised and home training programme

Acceptability and feasibility of other outcome measures that may be used for the multicentre RCT:
1. Domestic physical activity measured by tri-axial accelerometers (Sensewear pro 3). This is a valid measurement of daily activity to assess behaviour change
2. Quadriceps strength assessed by an adapted chair with a strain gauge
3. Venous blood sampling
4. Dual-energy X-ray absorptiometry (DEXA) scanning

Exacerbations of asthma
Patients will be asked to keep a diary of their exacerbations, treatment and unscheduled healthcare visits. Participants in both groups, along with their GPs, will receive a personalised management plan with guidance about initiating steroids for exacerbations. If participants present to the investigating team they will be reviewed by an independent clinician with the decision to commence treatment with oral prednisolone based on standard clinical guidelines. The patients will be asked to stop coming to the AT-PR sessions for any exacerbation requiring steroid treatment. If they are not recovered enough to start participation within 2 weeks they will be classified as a dropout. Similarly they will be excluded from the UC limb if they are not back to normal within 2 weeks to avoid bias.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

Patients with severe asthma (defined as asthma which remains symptomatic at steps 4-5 of the British Thoracic Society asthma guidelines), despite management for >6 months in the Glenfield Difficult Asthma Clinic (DAC), will be recruited. All patients will have a thorough diagnostic work up and a treatment strategy targeting eosinophillic airway inflammation to optimise control; exercise-induced asthma is often a reflection of poor control.

Participant type


Age group

Not Specified


Not Specified

Target number of participants

Stage 1: 2-30 patients; Stage 2: 6-8 focus groups of 6-10 healthcare professionals; Stage 3: 60 patients; Stage 4: patient representatives and the steering group commitee

Participant exclusion criteria

1. Severe exacerbation within a month of entry
2. Inability to exercise e.g. due to significant musculoskeletal or neurological abnormalities

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Glenfield Hospital
United Kingdom

Sponsor information


University Hospitals of Leicester NHS Trust (UK)

Sponsor details

c/o Mrs Carolyn Maloney
Research & Development Manager
United Kingdom

Sponsor type




Funder type


Funder name

National Institute for Health Research, Research for Patient Benefit Grant, PB-PG-0712-28063

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

National government


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2016 protocol in:

Publication citations

Additional files

Editorial Notes

24/10/2016: The following changes were made to the trial record: 1. The recruitment end date was changed from 10/11/2016 to 02/01/2017. 2. The overall trial end date was changed from 10/11/2016 to 10/09/2017. 29/03/2016: Publication reference added.